Posts

Dermatology PIN

Dermatology Conference 2023 THE 3rd INTERNATIONAL #CONFERENCE ON #Dermatology and Cosmetology Updated New Venue: #Bangkok #Thailand Register and join us to avail #CME points Read more: #Dermatology conference 2023 #internationalconference #conferences #Dermatology URL: https://dermatology.pulsusconference.com/

Study finds link between tumor microbiome and immune system in sarcoma patients

In a significant new study, UC Davis Comprehensive Cancer Center researchers have uncovered a link between a patient's microbiome and their immune system that can potentially be used to improve the treatment of soft tissue sarcoma. source https://www.news-medical.net/news/20230130/Study-finds-link-between-tumor-microbiome-and-immune-system-in-sarcoma-patients.aspx

Study identifies the DNA roots of resistance to targeted cancer therapy

A new clinical and preclinical study from UCLA Jonsson Comprehensive Cancer Center identifies the DNA roots of resistance to targeted cancer therapy, providing a possible strategy to address a vexing issue in cancer therapeutics. source https://www.news-medical.net/news/20230126/Study-identifies-the-DNA-roots-of-resistance-to-targeted-cancer-therapy.aspx

Study finds fewer cases of melanoma among regular users of vitamin D supplements

Fewer cases of melanoma were observed among regular users of vitamin D supplements than among non-users, a new study finds. source https://www.news-medical.net/news/20230109/Study-finds-fewer-cases-of-melanoma-among-regular-users-of-vitamin-D-supplements.aspx

Activated vitamin D3 inhibits arsenic-mediated carcinogenesis in certain skin cells, research shows

According to recent estimates, over 140 million people from 50 countries regularly get exposed to arsenic through drinking water. source https://www.news-medical.net/news/20221216/Activated-vitamin-D3-inhibits-arsenic-mediated-carcinogenesis-in-certain-skin-cells-research-shows.aspx

Novel monoclonal antibody therapy shows promising results in patients with moderate to severe atopic dermatitis

Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab-;a novel, patient-tailored monoclonal antibody therapy-;showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet. source https://www.news-medical.net/news/20221212/Novel-monoclonal-antibody-therapy-shows-promising-results-in-patients-with-moderate-to-severe-atopic-dermatitis.aspx

HIV-positive people are protected by Covid vaccines

People infected with HIV who receive antiretroviral therapy form antibodies against Sars-Cov-2 after being vaccinated against Covid with mRNA vaccines. source https://www.news-medical.net/news/20221209/HIV-positive-people-are-protected-by-Covid-vaccines.aspx